GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jeil Pharma Holdings 002620.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

6,900

+1.47%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩657.61bn

FY2016FY2025

Net income

₩14.64bn

FY2016FY2025

Free cash flow

−₩8.94bn

FY2016FY2025

Shareholders' equity

₩318.74bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩657.61bn₩779.82bn₩804.04bn₩792.96bn₩762.57bn₩762.00bn₩725.46bn₩142.74bn₩44.44bn₩617.28bn
Research and development₩45.20bn₩38.95bn₩46.04bn₩41.57bn₩39.67bn₩24.73bn₩22.45bn₩4.51bn₩700.9m₩22.36bn
Operating income₩44.92bn−₩54.44bn₩20.92bn−₩78.41bn−₩8.97bn₩33.84bn₩3.32bn₩11.73bn₩292.2m₩9.35bn
Net income₩14.64bn−₩51.16bn−₩16.25bn−₩74.56bn−₩3.48bn₩11.43bn−₩90.66bn₩7.07bn₩518.82bn₩7.89bn
Diluted earnings per share953.37-3,332.62-1,058.54-4,856.70-226.85744.65-5,905.81460.55139,343.22513.99

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩876.66bn₩890.43bn₩880.00bn₩865.68bn₩892.42bn₩887.40bn₩846.47bn₩920.09bn₩197.59bn₩491.99bn
Total liabilities₩407.55bn₩453.04bn₩477.81bn₩445.88bn₩392.11bn₩388.11bn₩363.44bn₩330.51bn₩27.15bn₩239.91bn
Debt₩16.54bn₩11.90bn₩10.50bn₩16.30bn₩18.53bn₩12.37bn₩122.27bn₩115.08bn₩678.6m₩56.96bn
Shareholders' equity₩318.74bn₩306.95bn₩319.46bn₩337.76bn₩411.73bn₩407.45bn₩393.48bn₩490.33bn₩166.74bn₩248.94bn
Shares outstanding15m15m15m15m15m15m15m15m4m15m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩390.3m₩4.54bn−₩4.42bn−₩20.80bn₩13.40bn−₩23.67bn₩25.22bn−₩3.43bn₩5.92bn₩11.36bn
Capital spending−₩9.33bn−₩6.86bn−₩9.84bn−₩21.41bn−₩23.69bn−₩9.81bn−₩37.69bn−₩50.20bn−₩2.94bn−₩30.33bn
Free cash flow−₩8.94bn−₩2.32bn−₩14.25bn−₩42.21bn−₩10.28bn−₩33.48bn−₩12.47bn−₩53.63bn₩2.98bn−₩18.97bn
Dividends paid−₩183.2m−₩1.13bn−₩1.13bn−₩1.47bn−₩1.59bn−₩1.59bn−₩1.52bn−₩223.3m−₩891.2m−₩764.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩164.70bn₩150.40bn₩154.43bn₩161.36bn₩159.78bn₩182.04bn₩203.97bn₩190.00bn
Operating income−₩9.94bn₩6.08bn₩6.70bn₩20.18bn₩6.98bn₩7.12bn₩4.05bn−₩4.24bn
Net income−₩3.55bn₩1.10bn₩7.31bn₩3.57bn₩1.46bn₩2.30bn−₩36.74bn−₩2.20bn
Diluted earnings per share-231.0171.83475.91232.7295.10149.64-2,393.44-143.40
Cash from operations−₩4.71bn₩447.0m₩1.97bn₩14.16bn−₩4.68bn−₩11.06bn₩2.16bn₩1.28bn
Capital spending−₩6.95bn−₩1.72bn−₩2.26bn−₩3.56bn−₩2.94bn−₩566.0m−₩1.70bn−₩1.25bn
Free cash flow−₩11.66bn−₩1.27bn−₩290.0m₩10.60bn−₩7.62bn−₩11.62bn₩454.0m₩31.0m
Total assets₩891.76bn₩878.26bn₩876.66bn₩860.96bn₩846.05bn₩872.54bn₩890.43bn₩881.86bn
Debt₩21.92bn₩16.48bn₩16.54bn₩16.60bn₩16.66bn₩11.90bn₩11.90bn₩11.90bn
Shareholders' equity₩314.47bn₩319.41bn₩318.74bn₩314.24bn₩310.34bn₩309.41bn₩306.95bn₩327.47bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-6.0%-2.9%1.0%
Operating income—5.8%13.1%
Net income—5.1%4.1%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-0.7%-2.2%-0.9%-0.1%
Net margin-2.5%-4.2%-2.6%5.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings8.4-2.4-11.1-3.2-70.528.5-2.956.00.3108.7
Price to sales0.20.10.20.30.30.40.42.83.01.4

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 27 Dec 2024.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year50.0050.0050.0065.0070.0070.0070.0060.00
  • 1-to-0.2926 reverse split · 17 Jul 2017
  • 10-for-1 split · 26 Apr 2006
  • 1.025-for-1 split · 4 Jan 2000
  • 1.021-for-1 split · 4 Jan 1999
  • 1.03-for-1 split · 4 Jan 1993
  • 7-for-4 split · 12 Apr 1990

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.